Basiliximab

Overview

Basiliximab, sold under the brand name Simulect, is a monoclonal antibody used to prevent rejection in kidney transplants. It is a chimeric mouse-human monoclonal antibody to the α chain (CD25) of the IL-2 receptor of T cells. It is used in combination with other medicines used to prevent organ rejection.[1][2] WP

The most common side effects (seen in more than 20% of patients) include constipation, urinary tract infections (infection of the structures that carry urine), pain, nausea (feeling sick), peripheral oedema (swelling), hypertension (high blood pressure), anemia (low red blood cell counts), headache, hyperkalaemia (high blood potassium levels), hypercholesterolaemia (high blood cholesterol levels), surgical wound complication, weight increase, increased serum creatinine (a marker of kidney problems), hypophosphataemia (low blood phosphate levels), diarrhea and upper respiratory tract infection (colds).[2] WP

Basiliximab was approved for medical use in the United States and in the European Union in 1998.[1][2][3] WP

Drug class

Immunosuppressants WP

From the Wikipedia article's infobox.

Uses, dosage and effects

Medical uses

Basiliximab is indicated for the prophylaxis of acute organ rejection in de-novo allogeneic renal transplantation. It is to be used concomitantly with ciclosporin for microemulsion- and corticosteroid-based immunosuppression, in people with panel reactive antibodies less than 80%, or in a triple maintenance immunosuppressive regimen containing ciclosporin for microemulsion, corticosteroids and either azathioprine or mycophenolate mofetil.[2] WP

Basiliximab is an immunosuppressant agent used to prevent immediate transplant rejection in people who are receiving kidney transplants, in combination with other agents. It has been reported that some cases of lichen planus have been successfully treated with basiliximab as an alternative therapy to cyclosporin. No short-term side effects have been reported.[4][5] WP

Pharmacology

Mechanism of action

Basiliximab competes with IL-2 to bind to the alpha chain subunit of the IL2 receptor on the surface of the activated T lymphocytes and thus prevents the receptor from signaling. This prevents T cells from replicating and also from activating B cells, which are responsible for the production of antibodies, which would bind to the transplanted organ and stimulate an immune response against the transplant.[6][7] WP

History

History

It is a Novartis product and was approved by the Food and Drug Administration (FDA) in 1998.[8] WP

Chemistry

Harm reduction information

No harm reduction data is on file for this compound yet. That means no dose, timing or combination data from PsychonautWiki or TripSit. Please don't guess a dose from similar compounds. If you have taken it and feel unwell, contact emergency services or a poison control center.

User reports

Pop culture

No references added yet.

Sources

1. Journal / agency Simulect- basiliximab injection, powder, for solution. 6 October 2022
2. Journal / agency Simulect EPAR. 31 October 2009
3. Journal / agency Basiliximab Product Approval Information - Licensing Action. 20 February 2009
4. Journal / agency MedlinePlus. Last Revised - 15 June 2012 Basiliximab Injection
5. Other Katsambas AD, Lotti TM. European handbook of dermatological treatments. 2003
6. Journal / agency Hardinger KL, Brennan DC, Klein CL. Selection of induction therapy in kidney transplantation. Transplant International. July 2013. doi:10.1111/tri.12043 · PMID 23279211
7. Journal / agency Basiliximab label
8. Journal / agency Waldmann TA. Immunotherapy: past, present and future. Nature Medicine. March 2003. doi:10.1038/nm0303-269 · PMID 12612576

Text and values on this page are quoted from Wikipedia (CC BY-SA 4.0). Each value links to the exact revision it came from.